{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-033726","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.943611+00:00","generated_at":"2026-06-04T22:20:55.216557+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Voyager Therapeutics names Toby Ferguson as Chief Medical Officer","bullets":["Employment starts March 25, 2024; base salary $485,000, target bonus 40%.","Granted inducement option for 210k shares and RSU for 105k shares, both time-vesting.","Dr. Ferguson previously VP, Head of Neuromuscular Development at Biogen (2013-2024).","Severance provides 12 months base salary and pro-rata bonus if terminated without cause or for good reason within 12 months post sale event.","At-will employment; standard non-compete and confidentiality obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-033726","json":"https://secwatch.observer/filing/0001104659-24-033726.json","markdown":"https://secwatch.observer/filing/0001104659-24-033726.md","text":"https://secwatch.observer/filing/0001104659-24-033726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924033726/0001104659-24-033726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924033726/tm247944d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:20:55.216557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}